Minjiang Chen

5.8k total citations · 2 hit papers
197 papers, 4.0k citations indexed

About

Minjiang Chen is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Minjiang Chen has authored 197 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 87 papers in Pulmonary and Respiratory Medicine, 77 papers in Oncology and 51 papers in Molecular Biology. Recurrent topics in Minjiang Chen's work include Lung Cancer Treatments and Mutations (42 papers), Cancer Immunotherapy and Biomarkers (36 papers) and Radiomics and Machine Learning in Medical Imaging (28 papers). Minjiang Chen is often cited by papers focused on Lung Cancer Treatments and Mutations (42 papers), Cancer Immunotherapy and Biomarkers (36 papers) and Radiomics and Machine Learning in Medical Imaging (28 papers). Minjiang Chen collaborates with scholars based in China, United States and Japan. Minjiang Chen's co-authors include Jiansong Ji, Mengzhao Wang, Qiaoyou Weng, Yan Xu, Jiansong Ji, Jing Zhao, Zhongwei Zhao, Shiji Fang, Wei Zhong and Gaofeng Shu and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Minjiang Chen

183 papers receiving 4.0k citations

Hit Papers

Targeted xCT‐mediated Ferroptosis and Protumoral Polariza... 2022 2026 2023 2024 2022 2023 40 80 120

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Minjiang Chen China 35 1.8k 1.2k 1.1k 903 581 197 4.0k
Xueli Bai China 37 1.8k 1.0× 515 0.4× 1.5k 1.3× 1.2k 1.3× 825 1.4× 154 4.2k
Rongcheng Luo China 35 2.4k 1.4× 686 0.6× 1.1k 0.9× 1.3k 1.4× 502 0.9× 207 4.2k
Yi Luo China 32 1.8k 1.0× 660 0.6× 854 0.8× 756 0.8× 587 1.0× 149 4.3k
Yingjiang Ye China 34 1.9k 1.1× 975 0.8× 1.7k 1.5× 1.1k 1.2× 906 1.6× 245 4.6k
Yoku Hayakawa Japan 41 1.6k 0.9× 978 0.8× 1.5k 1.4× 702 0.8× 807 1.4× 113 4.4k
Yasuhiro Hida Japan 42 3.0k 1.7× 815 0.7× 1.7k 1.5× 1.8k 2.0× 910 1.6× 162 5.5k
Ke Cao China 34 2.9k 1.7× 1.0k 0.9× 1.2k 1.1× 1.9k 2.1× 761 1.3× 151 5.3k
Pei‐Yi Chu Taiwan 37 2.6k 1.5× 726 0.6× 1.5k 1.3× 1.1k 1.3× 651 1.1× 210 4.7k
Rajkumar Savai Germany 42 2.5k 1.4× 2.1k 1.8× 1.2k 1.1× 1.2k 1.4× 1.4k 2.3× 124 5.5k

Countries citing papers authored by Minjiang Chen

Since Specialization
Citations

This map shows the geographic impact of Minjiang Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Minjiang Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Minjiang Chen more than expected).

Fields of papers citing papers by Minjiang Chen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Minjiang Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Minjiang Chen. The network helps show where Minjiang Chen may publish in the future.

Co-authorship network of co-authors of Minjiang Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Minjiang Chen. A scholar is included among the top collaborators of Minjiang Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Minjiang Chen. Minjiang Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lu, Tao, Yan Xu, Minjiang Chen, et al.. (2024). The outcomes of different regimens depend on the molecular subtypes of pulmonary large‐cell neuroendocrine carcinoma: A retrospective study in China. Cancer Medicine. 13(1). e6834–e6834. 7 indexed citations
2.
Du, Yang, Ruili Pan, Xiaotong Zhang, et al.. (2024). Tocilizumab for advanced non-small cell lung cancer with concomitant inflammatory cachexia: A single-centre study.. Journal of Clinical Oncology. 42(16_suppl). 2647–2647. 2 indexed citations
4.
Chen, Weiyue, Xia Li, Weibo Mao, et al.. (2024). Dual-energy computed tomography for predicting histological grading and survival in patients with pancreatic ductal adenocarcinoma. European Radiology. 35(5). 2818–2832. 2 indexed citations
5.
Du, Yang, Xiaoyan Liu, Ruili Pan, et al.. (2024). Tocilizumab for Advanced Non‐Small‐Cell Lung Cancer With Concomitant Cachexia: An Observational Study. Journal of Cachexia Sarcopenia and Muscle. 15(6). 2815–2825. 14 indexed citations
6.
Chen, Weiyue, Jiayi Ding, Gaofeng Shu, et al.. (2023). The role of metabolic reprogramming of oxygen‐induced macrophages in the dynamic changes of atherosclerotic plaques. The FASEB Journal. 37(3). e22791–e22791. 15 indexed citations
7.
Kong, Chunli, Liyun Zheng, Shiji Fang, et al.. (2023). Predictive Models for Colon Adenocarcinoma Diagnosis, Prognosis, and Immune Microenvironment Based on 2 Hypoxia-Related Genes: KDM3A and ENO3. Technology in Cancer Research & Treatment. 22. 2223937382–2223937382. 1 indexed citations
10.
Pan, Ruili, Minjiang Chen, Jing Zhao, et al.. (2022). Leptomeningeal enhancement in magnetic resonance imaging predicts poor prognosis in lung adenocarcinoma patients with leptomeningeal metastasis. Thoracic Cancer. 13(7). 1059–1066. 4 indexed citations
11.
Zhu, Jinyu, Bufu Tang, Yang Gao, et al.. (2021). Predictive Models for HCC Prognosis, Recurrence Risk, and Immune Infiltration Based on Two Exosomal Genes: MYL6B and THOC2. Journal of Inflammation Research. Volume 14. 4089–4109. 15 indexed citations
12.
Ni, Jun, Xiaotong Zhang, Hanping Wang, et al.. (2021). Clinical characteristics and prognostic model for extensive‐stage small cell lung cancer: A retrospective study over an 8‐year period. Thoracic Cancer. 13(4). 539–548. 9 indexed citations
13.
Kong, Chunli, Zhongwei Zhao, Weiyue Chen, et al.. (2021). Prediction of tumor response via a pretreatment MRI radiomics-based nomogram in HCC treated with TACE. European Radiology. 31(10). 7500–7511. 97 indexed citations
14.
Chen, Minjiang, Xiaoling Xu, Gaofeng Shu, et al.. (2021). Multifunctional Microspheres Dual-Loaded with Doxorubicin and Sodium Bicarbonate Nanoparticles to Introduce Synergistic Trimodal Interventional Therapy. ACS Applied Bio Materials. 4(4). 3476–3489. 11 indexed citations
15.
Zhang, Qianqian, Weiqian Chen, Xiuling Lv, et al.. (2019). Piperlongumine, a Novel TrxR1 Inhibitor, Induces Apoptosis in Hepatocellular Carcinoma Cells by ROS-Mediated ER Stress. Frontiers in Pharmacology. 10. 1180–1180. 42 indexed citations
16.
Lu, Haijiao, Shengzhe Zhang, Jie Wu, et al.. (2018). Molecular Targeted Therapies Elicit Concurrent Apoptotic and GSDME-Dependent Pyroptotic Tumor Cell Death. Clinical Cancer Research. 24(23). 6066–6077. 204 indexed citations
17.
Xu, Yan, Yiduo Sun, Jing Zhao, et al.. (2017). [Ocular Metastasis in Lung Cancer: a Retrospective Analysis in a Single Chinese Hospital and Literature Review].. SHILAP Revista de lepidopterología. 20(5). 326–333. 12 indexed citations
18.
Li, Jinmao, et al.. (2017). MicroRNA‐27a‐3p inhibits cell viability and migration through down‐regulating DUSP16 in hepatocellular carcinoma. Journal of Cellular Biochemistry. 119(7). 5143–5152. 31 indexed citations
19.
Zhao, Liangcai, Yongquan Zheng, Minjiang Chen, et al.. (2014). Systemic and characteristic metabolites in the serum of streptozotocin-induced diabetic rats at different stages as revealed by a 1H-NMR based metabonomic approach. Molecular BioSystems. 10(3). 686–693. 48 indexed citations
20.
Chen, Minjiang & Tao Liu. (2012). Guidelines for the management of adult lower respiratory tract infection. Chinese Journal of Asthma. 32(16). 1201–1206.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026